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Antidepressants increase adult hippocampal neurogenesis in animal models, but the
underlying molecular mechanisms are unknown. In this study, we used human hippocampal
progenitor cells to investigate the molecular pathways involved in the antidepressant-induced
modulation of neurogenesis. Because our previous studies have shown that antidepressants
regulate glucocorticoid receptor (GR) function, we specifically tested whether the GR
may be involved in the effects of these drugs on neurogenesis. We found that treatment
(for 3–10 days) with the antidepressant, sertraline, increased neuronal differentiation via
a GR-dependent mechanism. Specifically, sertraline increased both immature, double-
cortin (Dcx)-positive neuroblasts (þ16%) and mature, microtubulin-associated protein-2
(MAP2)-positive neurons (þ26%). This effect was abolished by the GR-antagonist, RU486.
Interestingly, progenitor cell proliferation, as investigated by 50-bromodeoxyuridine
(BrdU) incorporation, was only increased when cells were co-treated with sertraline and the
GR-agonist, dexamethasone, (þ14%) an effect which was also abolished by RU486.
Furthermore, the phosphodiesterase type 4 (PDE4)-inhibitor, rolipram, enhanced the effects
of sertraline, whereas the protein kinase A (PKA)-inhibitor, H89, suppressed the effects of
sertraline. Indeed, sertraline increased GR transactivation, modified GR phosphorylation and
increased expression of the GR-regulated cyclin-dependent kinase-2 (CDK2) inhibitors, p27
Kip1
and p57
Kip2. In conclusion, our data suggest that the antidepressant, sertraline, increases
human hippocampal neurogenesis via a GR-dependent mechanism that requires PKA
signaling, GR phosphorylation and activation of a specific set of genes. Our data point
toward an important role for the GR in the antidepressant-induced modulation of neurogenesis
in humans.
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Introduction
Several studies have shown that antidepressants
increase hippocampal neurogenesis in both animals
and humans,
1–5 and whether this increase in neuro-
genesis is necessary to overcome behavioral deficits
in animal models of depression is being intensely
debated.
5–16 However, the molecular pathways under-
lying such effects have not been described to date.
The effects of antidepressants on hippocampal neu-
rogenesis have been demonstrated for different,
chemically unrelated classes of antidepressants,
1
suggesting that a common molecular mechanism
may underlie their neurogenic potential. Identifying
such a mechanism would allow us to modulate
neurogenesis, and thereby possibly counteract some
of the neurobiological disturbances in depression.
Notably, recent studies have suggested that gluco-
corticoids are involved in the neurogenic action
of antidepressants.
12,17 For example, one study has
observed that antidepressants increase hippocampal
neurogenesis only in mice that are co-treated with
glucocorticoid hormones, but not in control mice.
12 Received 18 April 2010; revised 8 February 2011; accepted 9
February 2011; published online 12 April 2011
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sant-induced neurogenesis is also consistent with an
extensive literature, some from our own group, which
shows that antidepressants directly regulate the
function of the glucocorticoid receptor (GR).
18–24 The
GR is a ligand-activated nuclear transcription factor.
Upon ligand binding, the GR translocates into the
nucleus, binds to glucocorticoid response elements
on the DNA and subsequently activates gene
transcription (so called transactivation). Multiple
kinases have been reported to differentially phos-
phorylate the GR at its serine residues, S203, S211
and S226, an effect which regulates GR nuclear
translocation and GR-dependent gene transcrip-
tion.
25–29 Studies by us and others have shown that
antidepressants also induce GR nuclear translocation
and transactivation, which is, at least in part,
mediated by the cyclic AMP (cAMP)/protein kinase
A (PKA) cascade.
21–24,30–33 Moreover, the intracellular
availability of cAMP is tightly regulated by phospho-
diesterase type 4 (PDE4); and, consistent with
PKA-dependent regulation of the GR, the PDE4
inhibitor, rolipram, enhances GR activation by anti-
depressants.
30
Considering this body of evidence, we hypothe-
sized that antidepressants modulate adult hippocam-
pal neurogenesis via a GR-dependent mechanism that
requires PKA signaling and GR phosphorylation.
To test this hypothesis in a clinically relevant
model, we have used hippocampal progenitor cells
from humans. Using this in vitro model, we have been
able to separate the direct effects of antidepressants
on progenitor cells from any potential indirect
effects, which would be present in an in vivo model.
Moreover, we have examined the differential effects
of antidepressants (and glucocorticoid hormones)
on progenitor cell proliferation and differentiation,
as well as on GR phosphorylation, transactivation
and subsequent changes in gene expression. In all
our experiments, we have used the selective serotonin
reuptake inhibitor, sertraline, which has recently
been described as one of the most clinically effective
antidepressants.
34 Confirmatory replication experi-
ments have been conducted also using the tricyclic
antidepressants, amitriptyline and clomipramine.
Materials and methods
Cell culture
The multipotent, human hippocampal progenitor cell
line HPC03A/07 (provided by ReNeuron, Surrey, UK)
was used for all experiments. Further information on
this cell line and media components are available in
the Supplementary Materials.
Differentiation assay
To assess changes in neuronal differentiation,
HPC03A/07 cells were plated on black-sided 96-well
plates (Nunclon, Roskilde, Denmark) at a density of
1.1 10
4 cells per well. HPC03A/07 cells were cultured
in the presence of epidermal growth factor (EGF), basic
fibroblast growth factor (bFGF) and 4-hydroxytamoxi-
fen (4-OHT) for 72h, and then washed and cultured in
media without growth factors and 4-OHT for subse-
quent 7 days. Cells were treated with the antidepres-
sant sertraline (1mM), the GR-agonists, dexamethasone
(1mM) and cortisol (100mM), the GR-antagonist RU486
(50nM), the PDE4-inhibitor rolipram (100nM)o rt h e
PKA-inhibitor H89 (50nM). For these experiments,
cells were treated during the initial proliferation phase
and the subsequent differentiation phase (total treat-
ment of 10 days), or only during the proliferation phase
(72h), or only during the differentiation phase (7 days).
At the end of the total incubation time (10 days), cells
were fixed with 4% paraformaldehyde (PFA) for
20min at room temperature.
Proliferation assay
To assess progenitor cell proliferation, HPC03A/07
cells were plated as described above, and cultured
for 72h in the presence of growth factors and 4-OHT.
The synthetic nucleotide 50-bromodeoxyuridine
(BrdU, 10mM) was added to the culture media 4h
before the end of the incubation, and cells were fixed
as described above.
Immunocytochemistry
Neuronal differentiation was assessed by doublecor-
tin (Dcx), microtubulin-associated protein-2 (MAP2)
and neuron-specific class III -tubulin (TuJ1)
immunocytochemistry (Figure 1a, Supplementary
Figure 2a). Specificity of the MAP2 antibody
for mature neurons in our culture was confirmed
by co-labeling experiments and Western Blotting
(Supplementary Figure 11). Briefly, PFA-fixed cells
were incubated in blocking solution (5% normal goat
serum, Alpha Diagnostics, San Antonio, TX, USA) in
phosphate-buffered saline containing 0.3% Triton-X
for 2h at room temperature, and with primary
antibodies (rabbit anti-Dcx, 1:1000; mouse anti-
MAP-2 (HM), 1:500, Abcam, Cambridge, UK; rabbit
anti-TuJ1, 1:500, Sigma, St-Louis, MO, USA) at 41C
over night. Cells were incubated sequentially in
blocking solution for 30min, secondary antibodies
(Alexa 594 goat anti-rabbit, 1:1000 and Alexa 488 goat
anti-mouse, 1:500, Invitrogen, Paisley, UK) for 1h and
Hoechst 33342 dye (0.01mgml
 1, Invitrogen) for
5min at room temperature. The number of Dcx,
MAP2 and TuJ1 positive cells over total Hoechst
33342 positive cells was counted in an unbiased
setup with an inverted microscope (IX70, Olympus,
Hamburg, Germany) and ImageJ 1.41 software (http://
rsbweb.nih.gov). To assess progenitor cell prolifera-
tion, BrdU-containing cells were incubated with
hydrochloric acid (HCl, 2 N) for 15min at room
temperature, blocking solution for 60min at room
temperature, primary antibody (rat anti-BrdU, Sero-
tec, Oxford, UK. 1:500) at 41C over night and
secondary antibody (Alexa 488 goat anti-rat, 1:500,
Invitrogen) for 2h at room temperature. The number
of BrdU-positive cells over total Hoechst 33342
positive cells was determined as described above
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Molecular Psychiatry(see Figure 1a). Negative controls were incubated
with unspecific mouse IgGs (1:500, control for MAP-
2), rabbit IgGs (1:500, control for Dcx and TuJ1) or rat
IgGs (1:500, control for BrdU) in place of the specific
primary antibody (see Figure 1a).
Western blot analysis of GR phosphorylation
To assess changes in GR phosphorylation, HPC03A/
07 cells were treated for 1, 6 and 12h. Cells
were washed with ice cold phosphate-buffered saline
containing phosphatase inhibitors (Pierce, Rockford,
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Molecular PsychiatryIL, USA), scraped carefully from the flask and
centrifuged in a pre-cooled centrifuge for 10min at
3000rpm at 41C. Cell pellets were resuspendend in
protein extraction buffer (20mM Tris-HCl, 150mM
NaCl, 1mM EDTA, 1mM ethylene glycol tetraacetic
acid, 1% TritonX-100, 2nM calyculin A (Cell Signal-
ing, Danvers, MA, USA), 1  protease and phospha-
tase inhibitors (Pierce)), and incubated for 15min
at 41C. Protein lysates were centrifuged for 15min at
14000g at 41C. Protein concentrations were quanti-
fied using a bicinchoninic acid colorimetric assay
system (Merck, Nottingham, UK) (see Supplementary
Materials). Protein samples containing 50mgo f
total protein were boiled for 10min at 721Ci n1  
NuPAGE LDS sample buffer (Invitrogen) and 1 
NuPAGE sample-reducing agent (Invitrogen), and
subjected to reducing SDS-polyacrylamide gel elec-
trophoresis on 10% NuPAGE Bis–Tris gels for 1h at
200V. Proteins were electrophoretically transferred
to Immuno- Blot PVDF membranes (Bio-Rad labora-
tories, Hercules, CA, USA) at 110V for 1.5h at 41C.
Transfer efficiency was controlled by Ponceau S
staining and by pre-stained protein standards.
Unspecific binding sites were blocked for 1h in 5%
bovine serum albumin in Tris-buffered saline, and
membranes were immunoprobed with the polyclonal
rabbit anti-P-S203 (1:10000) and anti-P-S226 (1:1000)
antibodies (both from Dr Michael J Garabedian),
anti-P-S211 antibody (1:500; abcam), anti-GR59 anti-
body (1:500, Fisher) and anti-beta-actin antibody
(1:500, Biolegend, San Diego, CA, USA) in blocking
solution at 41C over night. Membranes were washed
with Tris-buffered saline containing 0.1% Tween-20,
and incubated with a horseradish peroxidase-con-
jugated swine anti-rabbit secondary antibody (1:2000,
DAKO, Glostrup, Denmark) in 5% non-fat dry milk in
Tris-buffered saline, for 1h at room temperature.
Membranes were washed in Tris-buffered saline con-
taining 0.1% Tween-20 and proteins were visualized
with enhanced chemiluminescence detection system
(GE Healthcare, UK). Data are expressed as fold change
from the vehicle-treated control condition.
GR transactivation assay
To determine changes in GR transactivation,
HPC03A/07 cells were treated with sertraline for 1,
6, 12, 24 and 72h. Nuclear protein extracts were
obtained using a commercially available nuclear
extraction kit (Active Motif, Rixensart, Belgium).
GR transactivation was analyzed using the enzyme-
linked immunosorbent assay-based TransAM GR
method (Active Motif), according to the manufacturer’s
instructions (see Supplementary Methods).
Gene expression analysis
RNA was isolated using RNeasy mini kit (Qiagen,
Crawley, UK) and processed for gene expression
analysis by quantitative real-time PCR using the
SYBR
s Green method (see Supplementary Methods).
Each sample was assayed in duplicate and each
target gene (GR, GRa, p27
Kip1, p57
Kip2, p21
Cip1, cyclin-
dependent kinase2 (CDK2), cyclin A2 (CCNA2),
cyclin D1 (CCND1), p53, human murine double
minute2 (HDM2), FK506-binding protein 5 (FKBP5),
serum/glucocorticoid-regulated kinase 1 (SGK1),
forkhead box O1 (FOXO1), growth-arrest and DNA-
damage-inducible  (GADD45B), brain-derived
neurotrophic factor (BDNF), p11 and -arrestin-2)
was normalized to the geometric mean of the three
reference genes glyceraldehyde 3-phosphate dehydro-
genase (GAPDH), beta-actin (ACTB) and beta-2-micro-
globulin (B2M). Pfaffl Method was used to determine
relative target gene expression. Data are expressed
as fold change from the vehicle-treated control con-
dition. Primer sequences are available upon request.
Drugs
All drugs and reagents were purchased from Sigma–
Aldrich (St Louis, MO, USA), unless otherwise stated.
Growth factors EGF and bFGF were purchased from
Figure 1 Antidepressants induce differentiation and neuronal maturation of HPC03A/07 human hippocampal progenitor
cells. Immunocytochemistry (ICC) for doublecortin (Dcx) and microtubulin-associated protein-2 (MAP2) was used to assess
neuronal differentiation and maturation, respectively. 50-bromodeoxyuridine (BrdU) incorporation and immunocytochem-
istry were used to assess progenitor cell proliferation (a). When HPC03A/07 cells were treated during the proliferation phase
(72h) and the subsequent differentiation phase (7 days), drug treatment had a significant effect on MAP2-positive neurons
(one-way analysis of variance, P<0.0001, F1,4=62.22, R
2=0.9120, n=5) and on Dcx-positive neuroblasts (one-way analysis of
variance, P=0.0007, F1,4=13.28, R
2=0.6713, n=5). Sertraline (SERT, 1mM) increased the number of MAP2-positive neurons
but did not alter the number of Dcx-positive neuroblasts, whereas dexamethasone (DEX, 1mM) decreased both. No effect was
observed upon co-treatment with SERT and DEX (b). When HPC03A/07 cells were treated only during the proliferation
phase, drug treatment had a significant effect on MAP2-positive neurons (one-way analysis of variance, P=0.0022,
F1,4=9.764, R
2=0.5824, n=5) and on Dcx-positive neuroblasts (one-way analysis of variance, P<0.0001, F1,4=44.44,
R
2=0.8724, n=5). SERT increased the number of Dcx-positive neuroblasts, without an effect on MAP2-positive neurons (c).
Treatment only during the differentiation phase did not have an effect on MAP2-positive neurons (one-way analysis of
variance, P=0.5699, F1,4=0.6184, R
2=0.1709, n=5) or on Dcx-positive neuroblasts (one-way analysis of variance, P=0.2146,
F1,4=2.127, R
2=0.4596, n=5) (d). Five independent experiments were conducted on five independent cultures (n=5),
four wells were analyzed per treatment condition in each experiment and three random, non-overlapping pictures were
analyzed for each well. All data are mean±s.e.m. *P<0.05, **P<0.01 and ***P<0.001 compared with the corresponding
vehicle-treated control.
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Molecular PsychiatryPeprotech (London, UK). Sertraline hydrochloride
and rolipram were dissolved in 100% dimethyl
sulfoxide dimethyl sulfoxide (DMSO); dexametha-
sone, hydrocortisone and RU486 were dissolved in
100% ethanol (EtOH); H89 dihydrochloride hydrate,
amitriptyline hydrochloride and clomipramine hy-
drochloride were dissolved in sterile, deionized
water. BrdU was dissolved in phosphate-buffered
saline fresh before use.
Statistical analysis
Data are presented as mean±s.e.m. All statistical
analyses were performed with GraphPad Prism 4.03
(Graph Pad Inc, La Jolla, CA, USA) on independent
biological replicates (indicated as n). One-way analy-
sis of variance with Newman–Keuls post-hoc test was
used for multiple comparisons among treatment
groups. Student’s t-test was used to compare means
of two independent treatment groups. P-values <0.05
were considered significant.
Results
Antidepressants and glucocorticoids regulate neuronal
differentiation of human hippocampal progenitor cells
To investigate the effects of antidepressants on neuro-
nal differentiation, we treated human hippocampal
progenitor cells (HPC03A/07) with sertraline for 72h
during proliferation, and for subsequent 7 days of
differentiation. Treatment with sertraline (1mM)i n -
creased the number of MAP2-positive neurons (by
28%; Figure 1b, left white column), but did not
significantly alter the number of Dcx-positive neuro-
blasts (Figure 1b, right white column). The specific GR-
agonist dexamethasone (1mM) decreased the number of
MAP2-positive neurons and of Dcx-positive neuro-
blasts (by 27 and 25%, respectively; Figure 1b, striped
columns). Treatment with cortisol induced the same
effects of dexamethasone (Supplementary Figure 1a).
Co-treatment of sertraline (1mM) and dexamethasone
(1mM) abolished the reduction in MAP2 and Dcx-
positive cells (Figure 1b, squared columns).
We also wanted to test whether treatment with
sertraline during progenitor cell proliferation is
sufficient to induce neuronal differentiation. We thus
treated cells only during the proliferation phase,
but not during the subsequent differentiation phase.
Under these conditions, sertraline did not alter
the number of MAP2-positive neurons (Figure 1c, left
white column) but increased the number of Dcx-
positive neuroblasts (by 16%; Figure 1c, right white
column), indicating that sertraline initiates neuronal
differentiation by an effect on progenitor cells, and
only induces neuronal maturation if continuously
present during neuronal differentiation (as shown in
Figure 1b). Dexamethasone reduced the number of
MAP2-positive neurons and of Dcx-positive neuro-
blasts (by 28 and 27%, respectively; Figure 1c, striped
column), an effect that was abolished by sertraline
co-treatment (Figure 1c, squared columns). Again,
cortisol had the same effects of dexamethasone
(Supplementary Figure 1b).
Interestingly, when we treated progenitor cells only
during the differentiation phase (7 days), but not
during the preceding proliferation phase (72h),
neither sertraline nor dexamethasone (or cortisol)
altered the number of MAP2-positive neurons or
of Dcx-positive neuroblasts (see Figure 1d and
Supplementary Figure 1c). Taken together, these
data indicate that the effects of antidepressants on
proliferating progenitor cells are essential to induce
neuronal differentiation into Dcx-positive neuro-
blasts, but not sufficient to promote their maturation
into MAP2-positive neurons. Additional experiments
in which cells were immunostained for the pan-
neuronal marker TuJ1, confirmed these findings (see
Supplementary Results and Supplementary Figure 2).
The effects of antidepressants on neurogenesis
are dependent on the GR
We specifically wanted to test whether the GR is
involved in the antidepressant-induced changes in
neurogenesis. We, therefore, co-treated progenitor
cells with sertraline and the GR-antagonist RU486
(50nM), during both proliferation and differentiation.
RU486 abolished the sertraline-induced increase in
the number of MAP2-positive neurons (Figure 2a,
white columns), thus confirming a role for the GR in
the neurogenic action of sertraline. As expected,
RU486 also eliminated the dexamethasone- (and the
cortisol-) induced decrease in MAP2-positive neurons
(Figure 2a, striped columns, Supplementary Figure
1). Furthermore, and consistent with the data
described above, RU486 abolished the sertraline-
induced increase in Dcx-positive neuroblasts, when
cells were treated only during the proliferation phase
but not during the subsequent differentiation phase
(Figure 2b, white columns). Treatment with RU486
alone showed no effect on neuronal differentiation at
the concentration used (50 nM) (data not shown).
Taken together, these data support the notion that
sertraline induces neuronal differentiation and pro-
motes neuronal maturation via a GR-dependent effect.
The effects of antidepressants on neurogenesis are
mediated by PKA signaling
Considering the role of PKA signaling in antid-
epressant drug action, we then wanted to examine
whether the effects of sertraline on neurogenesis
are mediated by the PDE4/PKA signaling cascade.
Therefore, we co-treated cells with sertraline and the
PKA-inhibitor, H89 (50nM) or the PDE4-inhibitor,
rolipram (100nM), which enhances PKA activity by
increasing cAMP levels. If treated during proliferation
and differentiation, rolipram enhanced the effect
of sertraline on MAP2-positive neurons (þ43% vs
sertraline alone), whereas H89 abolished it (Figure 3a,
white columns). Interestingly, rolipram also counter-
acted the dexamethasone-induced reduction in
MAP2-positive neurons, an effect that resembles the
action of sertraline (Figure 3a, striped columns).
Antidepressants, neurogenesis and glucocorticoid receptor
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proliferation phase, rolipram enhanced the sertra-
line-induced increase in Dcx-positive neuroblasts
(þ105% vs sertraline alone) while H89 abolished
this effect (Figure 3b, white columns). Rolipram also
counteracted the dexamethasone-induced reduction
in Dcx-positive neuroblasts, which again resembles
the action of sertraline (Figure 3b, striped columns).
Antidepressants regulate human hippocampal
progenitor cell proliferation
In all previous experiments, we examined the effects of
sertraline on neuronal differentiation. In order to study
the effects on cell proliferation, we treated progenitor
cells with sertraline for 72h, and incorporated BrdU
(10mM) during the last 4h of incubation. Treatment
with sertraline decreased the number of BrdU-positive
cells (by 16%; Figure 4a, left white column), which
supports the notion that progenitor cells stop prolifer-
ating in order to start to develop into neurons (as
displayed in Figure 1). Again, as for the effects on
neuronal differentiation, the effect of sertraline on
progenitor proliferation was abolished by RU486 co-
treatment (Figure 4a, right white column). Dexametha-
sone also reduced the number of BrdU-positive cells
(by 20%), an effect that was again abolished by RU486
(Figure 4a, striped columns). A similar effect was
observed using cortisol (Supplementary Figure 3a,
black columns). Interestingly, proliferation was signifi-
cantly increased only when progenitor cells were co-
treated with sertraline and dexamethasone (þ14%;
Figure 4a, squared columns) (or sertraline and cortisol,
Supplementary Figure 3a, squared columns). This
effect was again abolished by RU486 (Figure 4a,
squared columns). Treatment with RU486 alone
showed no effect on proliferation at the concentration
used (50 nM) (data not shown).
The same results were obtained using lower con-
centrations of BrdU (1mM) (Supplementary Figure 4),
using Ki67 immunocytochemistry (Supplementary
Methods and Supplementary Figure 12), or using the
tricyclic antidepressants, amitriptyline (1mM)a n d
clomipramine (1mM) (Supplementary Figure 5). Cell
death, as measured by propidium iodide live-staining,
was not affected by dexamethasone, cortisol, sertraline,
or dexamethasone and sertraline co-treatment in the
concentrations used in this study (see Supplementary
Materials and Supplementary Figure 10).
Finally, we wanted to investigate whether the
effects of sertraline on cell proliferation also require
PKA signaling. Indeed, rolipram enhanced the sertra-
line-induced reduction in cell proliferation (þ37%
vs sertraline alone), whereas H89 inhibited it ( 41%
vs sertraline alone; Figure 4b, white columns).
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Figure 2 The effects of sertraline on neuronal differentiation are dependent on the glucocorticoid receptor (GR). The
GR-antagonist RU486 (50nM) abolished the effect of SERT (1mM) and of DEX (1mM) on the number of microtubulin-associated
protein-2 (MAP2)-positive neurons (a) and on the number of doublecortin (Dcx)-positive neuroblasts (b). Three independent
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compared with SERT or DEX-treatment alone.
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methasone significantly increased proliferation
(þ17% vs vehicle; Figure 4b, striped columns),
which again resembles the effect of sertraline and
dexamethasone co-treatment. Finally, rolipram
further increased proliferation upon co-treatment
with sertraline and dexamethasone (þ59% vs dex-
amethasone þ sertraline), and this effect was abol-
ished by H89 (Figure 4c, squared columns). These
results support the notion that the effects of sertraline
on cell proliferation, as those on neuronal differentia-
tion, are mediated by PDE4/PKA signaling. It is
important to note that rolipram did not change
cell proliferation at the concentration used in
these experiments (that is, 100nM). However, higher
concentrations of rolipram (10mM) did indeed de-
crease cell proliferation via a GR-dependent effect
(Supplementary Figure 6), further supporting a role for
the interaction of PDE4/PKA and GR on neurogenesis.
Antidepressants modulate GR phosphorylation
via PKA signaling
In the experiments above, we have demonstrated that
sertraline, dexamethasone, and sertraline and dex-
amethasone co-treatment, have profoundly different
effects on neurogenesis, but all these effects are
mediated by the activation of the GR. One potential
explanation for these results is differential regulation
of GR phosphorylation by these three different
treatment conditions. Therefore, we investigated GR
phosphorylation at its serine residues S203, S211 and
S226 at 1, 6 and 12h of treatment. Our data indeed
show that sertraline, dexamethasone, and sertraline
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Figure 3 The effects of sertraline on neuronal differentiation are mediated by phosphodiesterase type 4 (PDE4)/protein
kinase A (PKA) signaling. Rolipram (100nM) increased the effect of SERT (1mM) on the number of microtubulin-associated
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Molecular Psychiatryand dexamethasone co-treatment, activate distinct
patterns of GR phosphorylation.
At the S203 residue, sertraline decreases GR
phosphorylation after 1h of treatment (0.5-fold
compared with control; Figure 5a, first white
column), whereas it increases phosphorylation at
6 and 12h (both by 1.6-fold, white columns). In line
with our data showing that the antidepressant effect
on neurogenesis is dependent on PKA, inhibition of
PKA by H89 abolishes all sertraline-induced changes
in S203 phosphorylation of the GR (Figure 5a).
In contrast, treatment with dexamethasone has the
opposite effect: it induces S203 phosphorylation after
1h of treatment (1.6-fold; Figure 5a, first striped
column), and it decreases phosphorylation after
6h (by 0.4-fold). Sertraline and dexamethasone
co-treatment shows yet a third time-dependent phos-
phorylation profile: Although no changes in S203
phosphorylation are observed after 1h (Figure 5a; first
squared column), phosphorylation is increased at
6 and 12h (by 1.5-fold and 1.7-fold, respectively;
squared columns). These co-treatment effects are
again blocked by H89. H89 alone did not show any
effect at the concentration used (data not shown).
Similar differential effects of the three treatment
conditions are present at the S211 phosphosite. Sertra-
line alone does not induce changes in S211 phosphor-
ylation at any time point (Figure 5b; white columns). In
contrast, dexamethasone strongly induces phosphory-
lation at S211 at 1, 6 and 12h of treatment (by ninefold,
twofold and threefold, respectively; striped columns).
Interestingly, co-treatment with sertraline and dexa-
methasone induces hyperphosphorylation at S211 to
levels higher than those induced by dexamethasone
alone (12-fold at 1h, 2.5-fold at 6h, 4-fold at 12h;
squared columns). This hyperphosphorylation at S211
is also counteracted by H89, confirming again that the
effect of sertraline on GR phosphorylation is indeed
mediated by PKA signaling (Figure 5b).
No significant treatment effects were observed
for phosphorylation at the S226 phosphosite
(Supplementary Figure 9).
Antidepressants induce GR transactivation and
enhance expression of the GR-dependent genes
p27
Kip1 and p57
Kip2
To further elucidate the molecular mechanisms
underlying the differential effects of sertraline,
dexamethasone, and sertraline and dexamethasone
co-treatment on neurogenesis, we compared the
effects of these three treatments on gene expression
of: the CDK2 inhibitors, p27
Kip1, p57
Kip2 and p21
Cip1;
the cell cycle-regulating genes p53, CCNA2, CCND1
and HDM2; and the glucocorticoid- and antidepres-
sant-responsive genes, FKBP5, SGK1, FOXO1,
GADD45B, GR, GRa, p11 and -arrestin-2. These
genes were chosen because they have all recently
been implicated in antidepressant drug action and
neurogenesis.
35–39,12,40–49 We conducted these experi-
ments during cell proliferation, because, as described
above, all effects (including those on differentiation)
were initiated during the proliferation phase.
Gene expression analysis revealed that the three
treatment conditions indeed activate distinct gene
expression profiles. Details of the gene expression
profiles and gene interactions for the three treatment
conditions (at 6, 12, 24, 48 and 72h) are described in
Figure 5, Supplementary Results and Supplementary
Figures 7 and 8. Here, we summarize the main
findings.
Sertraline increased expression of the CDK2
inhibitors, p27
Kip1 and p57
Kip2 (Figures 5c and e), an
effect that was particularly prominent after 12h of
treatment. Indeed, at this 12h time point, sertraline
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Figure 4 Effects of sertraline on progenitor cell proliferation. SERT (1mM) and DEX (1mM) decreased the number of
50-bromodeoxyuridine (BrdU)-positive cells. These effects were abolished by the glucocorticoid receptor (GR)-antagonist
RU486 (50nM). Co-treatment of DEX and SERTincreased the number of BrdU-positive cells. This effect was also abolished by
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Molecular Psychiatryalso induced GR transactivation (þ20%, Figure 5g;
an effect, which was abolished by H89, Figure 5h)
and reduced GR-expression (GRa mRNA by  30%,
GR mRNA by  40%, GR protein by  50%; also
blocked by H89; Supplementary Figure 7). The
increased expression of p27
Kip1 and p57
Kip2 was
also blocked by RU486 after 12h of treatment
(Figures 5d and f). Moreover, sertraline increased
p11 and -arrestin-2 (Supplementary Figure 8l,m),
and reduced GADD45B gene expression (Supplemen-
tary Figure 8j).
In contrast, dexamethasone reduced p27
Kip1 and
p57
Kip2 (Figures 5c and e) and upregulated GADD45B,
FKBP5, SGK1 and FOXO1 (Supplementary
Figure 8g-j).
The only genes, which were regulated only by
sertraline and dexamethasone co-treatment were the
cell cycle-promoting genes, CCND1 and HDM2,
which were both upregulated by this co-treatment
(Supplementary Figure 8e,f).
Discussion
In this study, we identify for the first time that the
antidepressant-induced changes in neurogenesis are
dependent on the GR. Specifically, the selective
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line, increases neuronal differentiation and promotes
neuronal maturation of human hippocampal progeni-
tor cells via a GR-dependent mechanism that is
associated with GR phosphorylation via PKA signal-
ing. Interestingly, this effect is only observed when
sertraline is present during the proliferation phase,
and it is accompanied by exit of cells from the
cell cycle, as shown by reduced proliferation and
increased GR-dependent expression of the CDK2
inhibitors, p27
Kip1 and p57
Kip2.
We and others have previously shown that anti-
depressants, including selective serotonin reuptake
inhibitors, induce GR nuclear translocation,
50,21,22
modulate GR-dependent gene transcription,
21,24,50,30
and change GR expression in cell culture,
51–55,19
animals
19,52,56–61,36 and humans.
19,62–64 In this study,
we identify for the first time a critical role for the GR
in the antidepressant effects on neurogenesis: first,
the sertraline-induced changes in neuronal differen-
tiation and progenitor cell proliferation are abolished
by the GR antagonist, RU486; and second, sertraline
modulates GR phosphorylation, induces GR transac-
tivation and changes the expression of GR-regulated
genes relevant to neurogenesis (see below).
Surprisingly, sertraline (like amitriptyline and
clomipramine) increases proliferation only in the
presence of glucocorticoids (dexamethasone or corti-
sol), but not by itself. The strength of our in vitro
model is that it separates the direct effects of
antidepressants on progenitor cells from the indirect
effects, which occur in vivo. Notably, increased
hippocampal cell proliferation by antidepressant
treatment in animals occurs always in the context of
endogenous glucocorticoid production—which is not
present in our in vitro system, unless when cells are
co-treated. Indeed, some animal studies have reported
that administration of exogenous glucocorticoids, or
circadian fluctuations of endogenous glucocorticoids,
are required for increased hippocampal cell prolifera-
tion upon antidepressant treatment.
12,17 Moreover, a
study on human post-mortem brain tissue has found
that antidepressants increase the number of neural
progenitor cells in patients with major depression to
levels above those present in controls, and depressed
patients are generally characterized by elevated
endogenous levels of glucocorticoids.
4 Taken together,
our in vitro findings and the above mentioned in vivo
studies indicate a pivotal role of the GR in the effects
of antidepressants on hippocampal progenitor
cells. It is important, however, to emphasize that our
findings also demonstrate that the molecular pro-
cesses that lead to increased neuronal differentiation
are activated directly by antidepressants alone and do
not require glucocorticoids. Our data suggest that
such complex GR-dependent regulation of cell fate is
the result of differential GR phosphorylation and
GR-dependent gene expression by antidepressants,
glucocorticoids and by antidepressant and glucocor-
ticoid co-treatment. Indeed, different GR phosphoiso-
forms have been reported to selectively occupy
promoters of different GR target genes, which may
therefore explain the diverse GR-dependent effects on
gene expression and neurogenesis that we observed in
our study (see below).
26,65–68
Further investigation of the molecular signaling
mechanisms, which underlie the effect of antidepres-
sants on neurogenesis showed that sertraline
increases GR transactivation after 12h of treatment.
At this time-point, expression of the CDK2 inhibitors,
p27
Kip1 and p57
Kip2, was strongly increased, and this
increase was blocked by RU486. p27
Kip1 and p57
Kip2
are GR-target genes that promote cell cycle exit and
increase neuronal differentiation in the developing
rat brain.
39,38,69 Therefore, increased expression of
these genes is consistent with our findings (discussed
above), which show that sertraline decreases prolif-
eration and initiates neuronal differentiation already
during the proliferation phase. It is also of note that
sertraline decreased GR expression (both at the
mRNA and the protein level) at the same time point
at which it induced GR transactivation. This is in
line with reports from the literature in both cell
culture and animal studies,
23,51,61 and probably results
from the increased GR transactivation.
19,23,24 Finally,
sertraline increased the expression of p11 and
-arrestin-2, which have both recently been impli-
cated in the antidepressant effects on neurogenesis
in vivo.
12,40,42,43 Interestingly, the cell cycle-promoting
genes, CCND1 and HDM2, were upregulated only
by sertraline and dexamethasone co-treatment, the
only condition which increases cell proliferation.
In contrast, dexamethasone increased expression
of the cell cycle-inhibiting genes, FOXO1 and
GADD45B, which may explain the reduced cell
proliferation and reduced neuronal differentiation
with this treatment. See also Supplementary Discus-
sion (‘Gene interactions’) and Supplementary Figure
13 for further discussion and a summary model.
Previous studies have proposed that antidepres-
sants modulate GR-function by cAMP/PKA signal-
ing.
30,31 Our data confirm and extend this model, by
showing that the GR-dependent changes in neurogen-
esis upon sertraline treatment are mediated by PKA.
Specifically, the PDE4-inhibitor, rolipram, which
increases cAMP levels and thus leads to higher PKA
activity, mimics and enhances the effects of sertraline
on neuronal differentiation and progenitor prolifera-
tion. Accordingly, the PKA inhibitor, H89, inhibits
the effects of sertraline. Furthermore, the sertraline-
induced changes in GR phosphorylation and GR
transactivation are also abolished by inhibition of
PKA. One potential mechanism by which sertraline
may cause this PKA activation is by liberating
G-protein alpha(s) subunits from membrane-asso-
ciated lipid rafts.
70–73 The subsequent cAMP produc-
tion and PKA activation may then ultimately induce
the GR phosphorylation, GR transactivation and
GR-dependent gene transcription, which we observed
in our study.
19,66,74,25,26 Interestingly, such a mechan-
ism may be independent of monoamine reuptake
systems, and could thus explain how neurogenesis is
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logical classes
3 (and, in our experiments, by both the
selective serotonin reuptake inhibitor, sertraline and
the tricyclic antidepressants, amitriptyline and clo-
mipramine).
In conclusion, our data suggest that anti-
depressants regulate differentiation and proliferation
of human hippocampal progenitor cells by a GR-
dependent mechanism that requires PKA signaling.
This is accompanied by changes in GR phosphoryla-
tion and GR-dependent gene transcription, including
increased expression of p27
Kip1 and p57
Kip2. Of note,
our findings point toward a complex regulation of
neurogenesis by antidepressants, with different
GR-dependent mechanisms that lead to enhanced
cell proliferation without changes in neuronal differ-
entiation, or enhanced neuronal differentiation in
the presence of decreased cell proliferation. It will
be important for future studies to elucidate the
impact of progenitor proliferation vs neuronal differ-
entiation on depression and other mental illnesses.
Moreover, modulation of GR phosphorylation and
GR-dependent gene transcription may represent a
future strategy of antidepressant drug treatment
to overcome neurogenesis-related disturbances in
depression.
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